Pamiparib

Overview

Pamiparib is under investigation in clinical trial NCT03933761 (Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy).

Indication

用于既往经过二线及以上化疗的伴有胚系BRCA(gBRCA)突变的复发性晚期卵巢癌、输卵管癌或原发性腹膜癌患者的治疗。

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS	2024/11/18	NCT06692491	Phase 2	Not yet recruiting	Peking University Shenzhen Hospital
Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)	2024/04/26	NCT06387056	Phase 2	Recruiting	The First Affiliated Hospital of Xiamen University
Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer	2022/12/15	NCT05652283	Phase 2	Active, not recruiting	Bai-Rong Xia
Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer	2022/09/02	NCT05526924	Phase 1	Recruiting	University of Chicago
Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer	2022/08/10	NCT05494580	Phase 1	Recruiting	Sun Yat-sen University
A Study to Explore Pamiparib Treatment in Epithelial Ovarian Cancer After Prior PARP Inhibitor Exposure	2022/08/05	NCT05489926	Phase 2	Active, not recruiting	Zhejiang Cancer Hospital
Pamiparib for Consolidation Treatment of Unprogressed LS-SCLC After Concurrent Chemoradiotherapy	2022/08/02	NCT05483543	Phase 2	Recruiting	Fudan University
A Study of Pamiparib Combined With Abiraterone Acetate in Neoadjuvant Treatment of Prostate Cancer	2022/05/17	NCT05376722	Phase 2	Recruiting	Hongqian Guo
Pamiparib in mCRPC With HRD or BRCA1/2 Mutation	2022/04/14	NCT05327621	Phase 2	Recruiting	Sun Yat-sen University
Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian Cancer	2021/09/16	NCT05044871	Phase 2	Completed	Tongji Hospital

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
No Health Canada approvals found for this drug.

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

Related News

BeiGene's BGB-16673 Shows Promise in Blood Cancer Treatment with Projected $9M Revenue by 2037

a year ago

• BeiGene's novel PROTAC drug candidate BGB-16673, targeting BTK and cereblon, is under development for multiple blood cancers including lymphomas and leukemia. • The drug's global revenue is projected to reach $9 million annually by 2037, with risk-adjusted NPV models providing conservative valuations for this clinical-stage asset. • BeiGene demonstrates strong financial growth with a 73.7% revenue increase to $2.46 billion in FY2023, while significantly reducing operating losses compared to previous year.

Combination Immunotherapies Show Promise in Pancreatic Cancer Treatment

4 years ago

• Combining anti-PD-(L)1 antibodies with hyaluronidase enhances tumor growth inhibition by remodeling the stroma and improving drug delivery in pancreatic cancer models. • Blocking IL-6 in combination with anti-PD-L1 antibodies inhibits tumor volume and increases survival in preclinical pancreatic cancer models, warranting clinical verification. • Combining CD40 agonists with PD-L1 blockade improves overall survival and promotes anti-tumor immunity in orthotopic pancreatic cancer mouse models. • Inhibiting the CXCL12/CXCR4 pathway alongside anti-PD-(L)1 therapy modulates immunosuppression and demonstrates synergistic effects in treating pancreatic cancer.

Help Us Improve

Your feedback helps us provide better drug information and insights.

AI-Powered Research

Premium Access